TSCAN THERAPEUTICS, INC. (TCRX) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$30.49M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$29.14M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$37.05M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$38.65M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$30.49M | (m) | $1.05M | (m) | $493.00K* | -$27.54M* | (m) | $23.40M | (m) | (m) |
| 2026-03-31 | Reported | (m) | -$29.14M | (m) | $982.00K | (m) | $70.00K | -$24.28M | (m) | $21.90M | (m) | (m) |
| 2025-09-30 | Reported | (m) | -$37.05M | (m) | $2.51M | (m) | $1.43M* | -$32.46M* | (m) | $31.69M | (m) | (m) |
| 2025-06-30 | Reported | (m) | -$38.65M | (m) | $3.08M | (m) | $1.28M* | -$33.27M* | (m) | $32.63M | (m) | (m) |
| 2025-03-31 | Reported | (m) | -$36.25M | (m) | $2.17M | (m) | $1.53M | -$37.59M | (m) | $29.79M | (m) | (m) |
| 2024-09-30 | Reported | (m) | -$32.62M | (m) | $1.05M | (m) | $1.37M* | -$27.92M* | (m) | $26.26M | (m) | (m) |
| 2024-06-30 | Reported | (m) | -$34.11M | (m) | $536.00K | (m) | $862.00K* | -$26.23M* | (m) | $26.88M | (m) | (m) |
| 2024-03-31 | Reported | (m) | -$31.37M | (m) | $566.00K | (m) | $705.00K | -$29.27M | (m) | $24.86M | (m) | (m) |
| 2023-09-30 | Reported | (m) | -$24.75M | (m) | $3.89M | (m) | $1.42M* | $8.02M* | (m) | $22.74M | (m) | (m) |
| 2023-06-30 | Reported | (m) | -$24.61M | (m) | $3.15M | (m) | $420.00K* | -$22.02M* | (m) | $21.23M | (m) | (m) |
| 2023-03-31 | Reported | (m) | -$22.74M | (m) | $6.80M | (m) | $838.00K | -$23.59M | (m) | $21.78M | (m) | (m) |
| 2022-09-30 | Reported | (m) | -$16.58M | (m) | $3.36M | (m) | $424.00K* | -$17.00M* | (m) | $15.03M | (m) | (m) |
| 2022-06-30 | Reported | (m) | -$15.25M | (m) | $4.06M | (m) | $1.89M* | -$13.37M* | (m) | $14.49M | (m) | (m) |
| 2022-03-31 | Reported | (m) | -$16.16M | (m) | $3.02M | (m) | $531.00K | -$20.12M | (m) | $14.69M | (m) | (m) |
| 2021-09-30 | Reported | (m) | -$15.84M | (m) | $2.41M | (m) | $853.00K* | -$13.64M* | (m) | $14.21M | (m) | (m) |
| 2021-06-30 | Reported | (m) | -$10.68M | (m) | $2.85M | (m) | $3.92M* | -$10.70M* | (m) | $10.80M | (m) | (m) |
| 2021-03-31 | Reported | (m) | -$7.92M | (m) | $2.03M | (m) | $2.96M | -$9.96M | (m) | $7.34M | (m) | (m) |
| 2020-09-30 | Reported | (m) | -$7.17M | (m) | $290.00K | (m) | $1.34M* | -$5.79M* | (m) | $5.81M | (m) | (m) |
| 2020-06-30 | Reported | (m) | -$5.62M | (m) | (m) | (m) | (m) | (m) | (m) | $4.50M | (m) | (m) |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$135.81M | (m) | $10.32M | (m) | $4.41M | -$135.32M | (m) | $114.15M | (m) | $0.00 |
| 2024-12-31 | Reported | (m) | -$134.82M | (m) | $2.82M | (m) | $3.83M | -$110.82M | (m) | $107.35M | (m) | (m) |
| 2023-12-31 | Reported | (m) | -$93.46M | (m) | $21.05M | (m) | $3.15M | -$61.36M | (m) | $88.15M | (m) | (m) |
| 2022-12-31 | Reported | (m) | -$66.64M | (m) | $13.54M | (m) | $4.22M | -$66.50M | (m) | $59.82M | (m) | (m) |
| 2021-12-31 | Reported | (m) | -$48.64M | (m) | $10.14M | (m) | $9.94M | -$48.68M | (m) | $44.95M | (m) | (m) |
| 2020-12-31 | Reported | (m) | -$26.23M | (m) | $1.08M | (m) | $4.24M | -$3.02M | (m) | $20.58M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B |